A Phase 3 interventional study of CSL312 in Hereditary Angioedema (HAE), sponsored by CSL Behring. Completed at 13 sites in 5 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Angioedemas, Hereditary by CSL Limited — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · CSL Limited.
Among the 11 studies in Angioedemas, Hereditary by CSL Limited, this one is the only one that started in 2023, is one of 5 in phase 3, and was the 8th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →1 of the 11 studies in Angioedemas, Hereditary by CSL Limited is open now, in 5 countries. Recruiting first, the newest first:
CSL Behring · Sites in United States, Austria, Canada and 2 more countries
Ages 12+
By country, each count listing its studies:
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 2 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 6 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2023.
This study's enrollment of 22 is below the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 61 across the 8 interventional studies, 259 across the 2 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Angioedemas, Hereditary by CSL Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ages 2-5 years and 6-11 years will have specific subcutaneous dosing schedules
Biological: CSL312
Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
Also known as: Garadacimab
Number of Participants With Treatment Emergent Adverse Events (TEAE)
Time frame: Up to Month 12
Percentage of Participants With TEAE
The percentage of participants was rounded to one place of decimal.
Time frame: Up to Month 12
Number of TEAE
Time frame: Up to Month 12
TEAE Rates Per Injection
The TEAE rate per injection was calculated as the number of TEAE/ number of injections. The number of injections was defined as the total injections a participant received during the Safety Evaluation Period under the dosing regimen to which the TEAE was assigned.
Time frame: Up to Month 12
TEAE Rates Per Participant-Year
The TEAE rate per participant year was calculated as number of TEAEs/ participant years. Participant-years of exposure were calculated as the sum of each participant's exposure duration (in years) under the specified dosing regimen or overall. For the time assigned to a dosing regimen, each study day was counted under the corresponding regimen.
Time frame: Up to Month 12
Maximum Concentration (Cmax) of CSL312 at Steady-state
Time frame: Up to Month 12
Trough Concentration (Ctrough) of CSL312 at Steady-state
Time frame: At Months 3, 4, 6, 9, 10, and 12
Time to Maximum Concentration (Tmax) of CSL312 at Steady-State
Time frame: Up to Month 12
Time-normalized Number of HAE Attacks Per Month
Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[Number of HAE attacks / Length of participant treatment in days\] \* 30.4375.
Time frame: Up to Month 12
Time-normalized Number of HAE Attacks Per Year
Time-normalized number of HAE attacks per year during treatment was calculated per participant as: \[Number of HAE attacks / Length of participant treatment in days\] \* 365.25.
Time frame: Up to Month 12
Time-normalized Number of HAE Attacks Treated With On-demand Treatment Per Month
The time-normalized number of HAE attacks per month treated with on-demand treatment were calculated as follows: \[(Number of HAE attacks treated with on - demand treatment during treatment period)/ Length of participant treatment in days\] ∗ 30.4375.
Time frame: Up to Month 12
Time-normalized Number of HAE Attacks Treated With On-demand Treatment Per Year
The time-normalized number of HAE attacks per year treated with on-demand treatment were calculated as follows: \[(Number of HAE attacks treated with on - demand treatment during treatment period)/ Length of participant treatment in days\] ∗ 365.25.
Time frame: Up to Month 12
Time-normalized Number of Moderate and/or Severe HAE Attacks Per Month
Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\] \* 30.4375.
Time frame: Up to Month 12
Time-normalized Number of Moderate and/or Severe HAE Attacks Per Year
Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\] \* 365.25.
Time frame: Up to Month 12
Percentage Reduction in the Time-normalized Number of HAE Attacks
The percentage reduction in the time-normalized number of HAE attacks was calculated within a participant as follows: 100\*\[ 1 - (Time-normalized number of HAE attacks per month during treatment period/Time-normalized number of HAE attacks per month from historical data)\].
Time frame: Up to Month 12
Number of Participants Experiencing at Least Greater Than or Equal to (>=) 50 Percent (%), >= 70%, >= 90%, or Equal to 100% (Attack-free) Reduction in the Time-normalized Number of HAE Attacks
A participant was classified as a responder if the percentage reduction in the time-normalized number of HAE attacks under treatment compared to the time-normalized number of HAE attacks documented in the medical records was \>= 50%. Percent Reduction = 100 \* \[1 - (time-normalized number of HAE attacks during corresponding time window / time-normalized number of HAE attacks based on historical data)\]. Here number of participants experiencing at least \>= 50%, \>= 70%, \>= 90%, or equal to 100% (Attack-free) reduction in the time-normalized number of HAE attacks are reported. The number of responders at each reduction category have been reported.
Time frame: Up to Month 12
Number of Participants Experiencing Serious Adverse Events (SAE), Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation
Time frame: Up to Month 12
Percentage of Participants Experiencing SAE, Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation
The percentage of participants was rounded to one decimal place.
Time frame: Up to Month 12
Number of Participants With TEAE by Severity
Severity of AE was assessed by the investigator and categorized as mild, moderate and severe where: Mild: AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.
Time frame: Up to Month 12
Percentage of Participants With TEAE by Severity
Severity of AE was assessed by the investigator and categorized as mild, moderate and severe where: Mild: AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention. The percentage of participants was rounded to one place of decimal.
Time frame: Up to Month 12
Number of Participants With Anti-CSL312 Antibodies
Time frame: At Day 1, Months 6 and 12
Percentage of Participants With Anti-CSL312 Antibodies
The percentage of participants was rounded to one place of decimal.
Time frame: At Day 1, Months 6 and 12
Number of Participants With Adverse Events of Special Interest (AESI)
AESI included severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators and suggestive events were independently identified for further review with a Standardized MedDRA Query (SMQ).
Time frame: Up to Month 12
Percentage of Participants With AESI
AESI included severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators and suggestive events were independently identified for further review with an SMQ. The percentage of participants was rounded to one place of decimal.
Time frame: Up to Month 12
FXIIa-mediated Kallikrein Activity
Time frame: At Months 3, 4, and 12 and pre-dose and post dose at Months 6, 9, and 10
Percent of Baseline FXIIa-mediated Kallikrein Activity
Percent of Baseline at Visit \[i\] = 100 \* (actual value at Visit \[i\] / Baseline value), where Baseline is defined as the most recent, non-missing value before the first IP administration (including unscheduled visits). Here unit of measure is Percent (%) of FXIIa-mediated Kallikrein Activity.
Time frame: At Months 3, 4, and 12 and pre-dose and post dose at Months 6, 9, and 10
Number of Participants With Laboratory Findings Reported as AE
Time frame: Up to Month 12
Percentage of Participants With Laboratory Findings Reported as AE
The participant data were rounded to one decimal place.
Time frame: Up to Month 12
This study was conducted at 9 sites in the United States, Australia, Canada, Germany, and Israel.
| Milestone | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Started | 6 | 16 |
| Completed | 6 | 16 |
| Not completed | 0 | 0 |
| Participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAE) | 5 | 11 |
The percentage of participants was rounded to one place of decimal.
| Percentage of participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Percentage of Participants With TEAE | 83.3 | 68.8 |
| Events | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Number of TEAE | 14 | 51 |
The TEAE rate per injection was calculated as the number of TEAE/ number of injections. The number of injections was defined as the total injections a participant received during the Safety Evaluation Period under the dosing regimen to which the TEAE was assigned.
| Number of TEAE per injection | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| TEAE Rates Per Injection | 0.39 | 0.27 |
The TEAE rate per participant year was calculated as number of TEAEs/ participant years. Participant-years of exposure were calculated as the sum of each participant's exposure duration (in years) under the specified dosing regimen or overall. For the time assigned to a dosing regimen, each study day was counted under the corresponding regimen.
| Number of TEAE per participant year | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| TEAE Rates Per Participant-Year | 2.34 | 3.21 |
| Nanograms per milliliter (ng/mL) | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Maximum Concentration (Cmax) of CSL312 at Steady-state | 30374.0 ± 13444.94 | 29100.0 ± 10988.08 |
| ng/mL | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Month 3 | — | 10494.7 ± 9956.38 |
| Month 4 | 3147.3 ± 2483.85 | — |
| Month 6 | 3478.0 ± 1897.32 | 9645.0 ± 4888.47 |
| Month 9 | — | 10003.3 ± 5232.68 |
| Month 10 | 4907.5 ± 2429.46 | — |
| Month 12 | 4211.0 ± 2597.93 | 8535.6 ± 5135.63 |
| Days | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Time to Maximum Concentration (Tmax) of CSL312 at Steady-State | 6.939 (5.95 to 7.96) | 6.985 (6.00 to 8.70) |
Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[Number of HAE attacks / Length of participant treatment in days\] \* 30.4375.
| Number of HAE attacks per month | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Time-normalized Number of HAE Attacks Per Month | 0.000 (0.0000 to 0.0843) | 0.000 (0.000 to 0.1682) |
Time-normalized number of HAE attacks per year during treatment was calculated per participant as: \[Number of HAE attacks / Length of participant treatment in days\] \* 365.25.
| Number of HAE attacks per year | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Time-normalized Number of HAE Attacks Per Year | 0.000 (0.000 to 1.0118) | 0.000 (0.000 to 2.0180) |
The time-normalized number of HAE attacks per month treated with on-demand treatment were calculated as follows: \[(Number of HAE attacks treated with on - demand treatment during treatment period)/ Length of participant treatment in days\] ∗ 30.4375.
| Number of HAE attacks per month | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Time-normalized Number of HAE Attacks Treated With On-demand Treatment Per Month | 0.000 (0.000 to 0.0843) | 0.000 (0.000 to 0.0850) |
The time-normalized number of HAE attacks per year treated with on-demand treatment were calculated as follows: \[(Number of HAE attacks treated with on - demand treatment during treatment period)/ Length of participant treatment in days\] ∗ 365.25.
| Number of HAE attacks per year | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Time-normalized Number of HAE Attacks Treated With On-demand Treatment Per Year | 0.000 (0.000 to 1.0118) | 0.000 (0.000 to 1.0203) |
Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\] \* 30.4375.
| Number of HAE attacks per month | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Time-normalized Number of Moderate and/or Severe HAE Attacks Per Month | 0.000 (0.000 to 0.0843) | 0.000 (0.000 to 0.0843) |
Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\] \* 365.25.
| Number of HAE attacks per year | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Time-normalized Number of Moderate and/or Severe HAE Attacks Per Year | 0.000 (0.000 to 1.0118) | 0.000 (0.000 to 1.0118) |
The percentage reduction in the time-normalized number of HAE attacks was calculated within a participant as follows: 100\*\[ 1 - (Time-normalized number of HAE attacks per month during treatment period/Time-normalized number of HAE attacks per month from historical data)\].
| Percentage reduction in HAE attacks | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Percentage Reduction in the Time-normalized Number of HAE Attacks | 99.297 ± 1.7211 | 93.535 ± 12.9513 |
A participant was classified as a responder if the percentage reduction in the time-normalized number of HAE attacks under treatment compared to the time-normalized number of HAE attacks documented in the medical records was \>= 50%. Percent Reduction = 100 \* \[1 - (time-normalized number of HAE attacks during corresponding time window / time-normalized number of HAE attacks based on historical data)\]. Here number of participants experiencing at least \>= 50%, \>= 70%, \>= 90%, or equal to 100% (Attack-free) reduction in the time-normalized number of HAE attacks are reported. The number of responders at each reduction category have been reported.
| Participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| >= 50% | 6 | 15 |
| >= 70% | 6 | 15 |
| >= 90% | 6 | 11 |
| Attack free (Reduction of 100%) | 5 | 10 |
| Participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| SAE | 0 | 1 |
| Experiencing Death | 0 | 0 |
| Related TEAE | 1 | 3 |
| TEAE leading to study discontinuation | 0 | 0 |
The percentage of participants was rounded to one decimal place.
| Percentage of participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| SAE | 0 | 6.3 |
| Experiencing Death | 0 | 0 |
| Related TEAE | 16.7 | 18.8 |
| TEAE leading to study discontinuation | 0 | 0 |
Severity of AE was assessed by the investigator and categorized as mild, moderate and severe where: Mild: AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.
| Participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Mild | 4 | 9 |
| Moderate | 3 | 5 |
| Severe | 0 | 2 |
Severity of AE was assessed by the investigator and categorized as mild, moderate and severe where: Mild: AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention. The percentage of participants was rounded to one place of decimal.
| Percentage of participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Mild | 66.7 | 56.3 |
| Moderate | 50.0 | 31.3 |
| Severe | 0 | 12.5 |
| Participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Day 1: Positive | 0 | 0 |
| Month 6: Positive | 0 | 2 |
| Month 12: Positive | 0 | 2 |
The percentage of participants was rounded to one place of decimal.
| Percentage of participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Day 1: Positive | 0 | 0 |
| Month 6: Positive | 0 | 13.3 |
| Month 12: Positive | 0 | 12.5 |
AESI included severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators and suggestive events were independently identified for further review with a Standardized MedDRA Query (SMQ).
| Participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Investigator | 0 | 0 |
| SMQ | 1 | 3 |
AESI included severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators and suggestive events were independently identified for further review with an SMQ. The percentage of participants was rounded to one place of decimal.
| Percentage of participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Investigator | 0 | 0 |
| SMQ | 16.7 | 18.8 |
| DeltaA405 nanometer per minute | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Month 3 | — | 0.2039 ± 0.0927 |
| Month 4 | 0.2632 ± 0.0904 | — |
| Month 6: Pre-dose | 0.2932 ± 0.0679 | 0.1863 ± 0.0979 |
| Month 6: Post-dose | — | 0.1162 ± 0.0811 |
| Month 9: Pre-dose | — | 0.1910 ± 0.0889 |
| Month 9: Post-dose | — | 0.1145 ± 0.1606 |
| Month 10: Pre-dose | 0.2703 ± 0.0400 | — |
| Month 10: Post-dose | 0.1002 ± 0.1190 | — |
| Month 12 | 0.2368 ± 0.0938 | 0.2049 ± 0.0870 |
Percent of Baseline at Visit \[i\] = 100 \* (actual value at Visit \[i\] / Baseline value), where Baseline is defined as the most recent, non-missing value before the first IP administration (including unscheduled visits). Here unit of measure is Percent (%) of FXIIa-mediated Kallikrein Activity.
| % FXIIa-mediated Kallikrein Activity | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Month 3 | — | 122.45 ± 84.860 |
| Month 4 | 166.43 ± 149.522 | — |
| Month 6: Pre-dose | 168.12 ± 117.752 | 128.12 ± 134.291 |
| Month 6: Post-dose | — | 62.54 ± 38.197 |
| Month 9: Pre-dose | — | 114.56 ± 88.924 |
| Month 9: Post-dose | — | 70.07 ± 54.403 |
| Month 10: Pre-dose | 179.26 ± 149.818 | — |
| Month 10: Post-dose | 98.41 ± 151.830 | — |
| Month 12 | 180.09 ± 165.106 | 130.44 ± 105.945 |
| Participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Number of Participants With Laboratory Findings Reported as AE | 0 | 1 |
The participant data were rounded to one decimal place.
| Percentage of participants | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Percentage of Participants With Laboratory Findings Reported as AE | 0 | 6.3 |
Collected over Up to Month 15. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CSL312 (Garadacimab) Q2M | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| CSL312 (Garadacimab) Q1M | 0/16 (0%) | 1/16 (6.3%) | 11/16 (68.8%) |
| Event | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Skull fractureInjury, poisoning and procedural complications | 0/6 | 1/16 |
| Event | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/6 | 6/16 |
| Ear infectionInfections and infestations | 1/6 | 1/16 |
| COVID-19Infections and infestations | 1/6 | 0/16 |
| Gastroenteritis norovirusInfections and infestations | 1/6 | 0/16 |
| Gastroenteritis viralInfections and infestations | 1/6 | 0/16 |
| Otitis mediaInfections and infestations | 1/6 | 0/16 |
| Periorbital cellulitisInfections and infestations | 1/6 | 0/16 |
| Viral infectionInfections and infestations | 1/6 | 0/16 |
| Viral upper respiratory tract infectionInfections and infestations | 1/6 | 0/16 |
| Injection site painGeneral disorders | 1/6 | 0/16 |
Analysis was performed on safety analysis set (SAS). The SAS comprised all participants enrolled in the study who received at least 1 dose of the investigational product (IP).
| Age, Categorical(Participants) | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M | Total |
|---|---|---|---|
| <=18 years | 6 | 16 | 22 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(Years) | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M | Total |
|---|---|---|---|
| Mean | 3.7 ± 1.51 | 9.3 ± 1.34 | 7.7 ± 2.88 |
| Sex: Female, Male(Participants) | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M | Total |
|---|---|---|---|
| Female | 1 | 4 | 5 |
| Male | 5 | 12 | 17 |
| Ethnicity (NIH/OMB)(Participants) | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 6 | 14 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CSL312 (Garadacimab) Q2M | CSL312 (Garadacimab) Q1M | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 6 | 15 | 21 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.
Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
Ran from May 2023 to primary completion in Nov 2025, 29 months.
Results were first posted in Jun 2026, 6 months after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 29 months is above that.
Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Garadacimab